Scientific Sessions 2024  /  The Future of Lipid Management: Using Lessons From Our Past  /  The Discovery of the LDL-Receptor and It's Potential as a Target
Logo

American Heart Association

  112
  0

Final ID:

The Discovery of the LDL-Receptor and It's Potential as a Target

  • Goldstein, Joseph  ( UTSW MEDICAL CTR , Dallas , Texas , United States )
  • Brown, Michael  ( UT SOUTHWESTERN MED CTR , Dallas , Texas , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Joseph Goldstein: No Answer | Michael Brown: No Answer | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Future of Lipid Management: Using Lessons From Our Past

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

The Evolution from Statins to Monoclonal Antibodies and Antisense Technology for Lipid Lowering

Michos Erin, Crooke Rosanne, Shapiro Michael

More abstracts from these authors:
The Next Era in Cardiometabolic Treatment

Ballantyne Christie

Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis

Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available